1 / 29

Partner presentation

This document outlines the collaborative efforts of various esteemed institutions in the field of cancer research. Key partners include Karolinska Institutet, Institut Curie, Danish Cancer Society, and many more, each contributing to significant work packages focused on critical areas like early detection, therapeutic strategies, kinome analysis, and biobanking. Through shared resources and expertise, these institutions strive to advance knowledge and develop innovative solutions in cancer prevention, detection, and treatment. Together, they aim to enhance global health outcomes through collaborative innovation.

kosey
Download Presentation

Partner presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Partner presentation

  2. Partner 1 – Karolinska Institutet • Ulrik Ringborg • WP15 Ethical issues – WP leader Rolf Lewensohn KI • WP16 Management – WP leader Ulrik Ringborg KI

  3. Partner 2 – Institut Curie • Sergio Roman-Roman Participating in: • WP3 Early detection • WP4 Kinome analysis • WP6 Therapeutic strategies • WP8 Technological structures & resources for discovery • WP10 Biobanking • WP11 Epidemiology

  4. Partner 3 – Danish Cancer Society • Julio E. Celis • WP1Scientificcoordination – WP leader J. E. Celis Participating partners: • DCS • INT • IGR • NKI • ERASMUS MC • UCAM • ECPC

  5. Partner 4 – Oslo University Hospital, Radiumhospitalet • Anne-Lise Børresen-Dale • WP3 Early detection – WP leader A-L. Børresen-Dale together with INT Participating partners: - KI - Inst Curie - DCS - OUS - INT - DKFZ - IGR - IARC - UOXF.HD - IEO - CHRIS - NIO - NKI - UCAM - IJB - LUMC

  6. Partner 5 – Spanish National Cancer Research Centre • Mariano Barbacid • WP7 Mouse models – WP leader M. Barbacid Participating partners: - CNIO - NKI - UCAM

  7. Partner 6 – Fondazione IRCCS IstitutoNazionaledeiTumori • Marco A. Pierotti • WP3 Early detection – WP leader M. A. Pierotti together with OUS Participating partners: - KI - Inst Curie -DCS - OUS - INT - DKFZ - IGR - IARC - UOXF.HD - IEO - CHRIS - NIO - NKI - UCAM - IJB - LUMC

  8. Partner 7 – German Cancer Research Centre • Otmar D. Wiestler • WP11 Epidemiology – WP-leaders Hermann Brenner & Cornelia Ulrich Participating partners: - KI - Inst Curie - DCS - OUS - INT - DKFZ - IARC - IEO - CHRIS - NKI - UCAM - ERASMUS MC - IJB

  9. Partner 8 – Institut Gustave Roussy • Alexander M. M. Eggermont • WP6 Therapeutic strategies – WP-leader Thomas Tursz Participating partners: KI, Inst Curie, DCS, OUS, CNIO, INT, DKFZ, IGR, UOXF.HD, IEO, CHRIS, NIO, NKI, ERASMUS MC, UCAM, IJB, VHIO, EORTC • WP12 Quality assurance/designation – WP-leader Mahasti Saghatchian together with NKI Participating partners: IGR, IEO, NKI, OECI

  10. Partner 9 – International Agency for Research on Cancer • Christopher Wild • WP2 Prevention – WP leader C. Wild Participating partners: IGR, IEO, NKI, OECI

  11. Partner 10 – Oxford Cancer Centre • Nicholas La Thangue Participating in: • WP3 Early detection • WP6 Therapeutic strategies • WP8 Technological structures & resources for discovery

  12. Partner 11 – IstitutoEuropeo di Oncologia • Umberto Veronesi Participating in: • WP2 Prevention • WP3 Early detection • WP6 Therapeutic strategies • WP8 Technological structures & resources for discovery • WP10 Biobanking • WP11 Epidemiology • WP12 Quality assurance/designation

  13. Partner 12 – Christie Foundation Trust • Nicholas Jones Participating in: • WP2 Prevention • WP3 Early detection • WP6 Therapeutic strategies • WP10 Biobanking • WP11 Epidemiology

  14. Partner 13 – National Institute of Oncology • Miklós Kasler Participating in: • WP3 Early detection • WP6 Therapeutic strategies • WP8 Technological structures and resources for discovery • WP10 Biobanking

  15. Partner 14 - Netherlands Cancer Institute • Anton Berns • WP4 Kinome analysis – WP leader René Bernards Participating partners: IGR, IEO, NKI, OECI • WP8 Technological structures & resources for discovery – WP leader René Bernards, Participating partners: KI, Inst Curie, DCS, OUS, CNIO, INT, DKFZ, IGR, UOXF.HD, IEO, NIO, NKI, EMC, UCAM • WP12 Quality assurance/designation – WP leader Wim van Harten together with IGR Participating partners: IGR, IEO, NKI, OECI

  16. Partner 15 – Erasmus University Medical Centre Rotterdam • Alexander M.M. Eggermont • WP10 Biobanking – WP leader Peter Riegman Participating partners: - KI - Inst Curie - OUS - CNIO - INT - IARC - IEO - CHRIS - NIO - NKI - EMC - UCAM - FIVO - OECI

  17. Partner 16 – University of Cambridge, Dept of Oncology • Carlos Caldas Participating in: • WP3 Early detection • WP4 Kinome analysis • WP6 Therapeutic strategies • WP7 Mouse models • WP8 Technological structures & resources for discovery • WP10 Biobanking • WP11 Epidemiology

  18. Partner 17 – Institut Jules Bordet • Dominique de Valeriola Participating in: • WP3 Early detection • WP6 Therapeutic strategies • WP11 Epidemiology

  19. Partner 18 – European MolecularBiologyLaboratory • Jan Korbel • WP9 Bioinformatics – WP leader Jan Korbel Participating partners: - KI - IGR - EMC - EMBL

  20. Partner 19 – The Institute of Cancer Research • Alan Ashworth Participating in: • WP5 Targeting the DNA damage response

  21. Partner 20 – Leiden University Medical Centre • Nelleke Gruis Participating in: • WP2 Prevention • WP3 Early detection

  22. Partner 21 – FundacíonInstitutioValencian de Oncologia • Antonio Llombart Bosch Participating in: • WP10 Biobanking

  23. Partner 22 – IstitutoTumori ”Giovanni Paolo II” • Angelo Paradiso • WP13 Education – WP leader Angelo Paradiso Participating partners: - NCI Bari - ECCO - OECI

  24. Partner 23 – Vall d´HebronInsitute of Oncology • José Baselga Participating in: • WP6 Therapeutic strategies

  25. Partner 24 – eCancer • Gordon McVie • WP14 Communication and dissemination – WP leader Gordon McVie Participating partners: - ECMS - ECCO - OECI - ECPC

  26. Partner 25 –European CanCer Organisation • Michel Ballieu Participating in: • WP1 Scientific coordination, oncopolicy • WP13 Education • WP14 Communication and dissemination

  27. Partner 26 –Organisation of the European Cancer Institutes • Marco A. Pierotti & Claudio Lombardo Participating in : • WP10 Biobanking • WP12 Quality assessment, accreditation and metrics • WP13 Education • WP14 Communication and dissemination

  28. Partner 27 – European Cancer Patient Coalition • Tom Hudson & Denis Horgan Participating in: • WP1 Scientific coordination • WP14 Communication & dissemination

  29. Partner 28 – European Organisation of Research & Treatment of Cancer • Françoise Meunier Participating in: • WP1 Scientific Coordination • WP6 Therapeutic Strategies • WP10 Biobanking

More Related